Last Updated : July 24, 2024
Details
Generic Name:
treosulfan
Project Status:
Not filed
Therapeutic Area:
Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric)
Manufacturer:
Medexus Pharmaceuticals Inc.
Brand Name:
Trecondyv
Project Line:
Reimbursement Review
Project Number:
NS0030-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
In combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in pediatric patients older than 1 year old with AML or MDS.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024